OPTHEA LIMITED news, videos and press releases
For more news please use our advanced search feature.
OPTHEA LIMITED - More news...
OPTHEA LIMITED - More news...
- Opthea Announces Decision to Discontinue Wet AMD Trials
- Opthea Announces COAST Phase 3 Trial Topline Results
- Opthea Announces Phase 2b Wet AMD Publication
- Opthea Reports Half Year Results and Business Updates
- Opthea Completes Drug Product PPQ Campaign
- Opthea Completes COAST Final Week 52 Patient Visit
- Opthea to Present at Oppenheimer Healthcare Conference
- Opthea Wet AMD Data Featured at Macula Society Meeting
- Opthea to Host Investor Days in New York and Australia
- Opthea Announces Publication in Diabetic Macular Edema
- Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
- Opthea’s Wet AMD Program to be Featured at FLORetina 2024
- Opthea to Participate in Citi 2024 Global Healthcare Conference
- Opthea Appoints Kathy Connell to Board of Directors
- Opthea’s Wet AMD Program Featured at Ophthalmology Events
- Opthea to Participate in November Investor Conferences
- Opthea Files Notice of Annual General Meeting
- Opthea Wet AMD Program to be Presented at Innovate Retina
- Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025
- Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
- Opthea Joins the S&P/ASX 300 Index
- Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
- Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
- Opthea Announces Executive Leadership Changes and Senior Hires
- Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
- Opthea Reports Full-Year Financial Results and Business Updates
- Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024
- Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
- Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer
- Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD
